HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results